Loading in 5 sec....

The Posterior Probability of Dissolution EquivalencePowerPoint Presentation

The Posterior Probability of Dissolution Equivalence

- 334 Views
- Updated On :
- Presentation posted in: General

The Posterior Probability of Dissolution Equivalence. David J LeBlond 1 , John J Peterson 2 and Stan Altan 3 ) 1 Exploratory Statistics, Abbott, david.leblond@abbott.com 2 Research Statistics Unit, GlaxoSmithKline Pharmaceuticals 3 Pharmaceutical R&D, Johnson & Johnson .

The Posterior Probability of Dissolution Equivalence

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

The Posterior Probability of Dissolution Equivalence

David J LeBlond 1 , John J Peterson 2 and Stan Altan 3)

1 Exploratory Statistics, Abbott,david.leblond@abbott.com

2 Research Statistics Unit, GlaxoSmithKline Pharmaceuticals

3 Pharmaceutical R&D, Johnson & Johnson

Midwest Biopharmaceutical Statistical Workshop

Muncie, Indiana

May 25, 2011

- Objective
- Background
- Why dissolution?
- Equivalence defined
- Current practice

- Why a Bayesian approach?
- Posterior probability defined
- MCMC
- Examples
- Equivalence of 2 lots
- Equivalence of 2 processes (multiple lots)
- Model dependent comparisons

- Summary

MBSW May 25, 2011

- Make this tool available to you so you can use it if you want to.
- Statistical Modeling
- Software (R, WinBUGS)
- Example Data & Code
- david.leblond@abbott.com

MBSW May 25, 2011

- Surrogate measure of in-vivo dissolution
- In-vivo dissolution rate affects drug bio-availability
- Bio-availability may affect PK (blood levels)
- Blood levels may affect safety and efficacy
- Compendial requirement for most solid oral dosage forms
- Need to show “equivalence” for process/ method change or transfer to obtain a bio-waiver.
- Need to show “non-equivalence” to prove in-vitro method can detect formulation / process differences.

MBSW May 25, 2011

100

% Dissolved

0

Time

- 1 tablet/ stirred vessel
- 1 run usually = 6 tablets
- solution sampled at fixed intervals

- samples assayed
- cumulative concentration
- expressed as % of dosage form Label Content (%LC)
- Are and “equivalent”?

MBSW May 25, 2011

- Identify parameter space based on
- Difference in Dissolution at multiple time points
- Difference in profile model parameters
- Condensed univariate distance measure

- Establish similarity region
- Constraints on parameter space
- Based on “customer requirements”

- Obtain distance estimate from data
- Conforms to parameter space

- Equivalence: distance estimate is “sufficiently contained within” the similarity region.

?

MBSW May 25, 2011

D2

0

D1

0

- parameter space: Dissolution differences, Di, at p time points.
- similarity region:
- distance estimate = (point estimate)
- Equivalence: (no measure of uncertainty)

MBSW May 25, 2011

TOST (one dimensional)

5%

5%

8%

2%

Yes

No

“MOST” (multi-dimensional)

No

Maybe

Yes

MBSW May 25, 2011

- Must choose similarity region shape.
- Must choose confidence region shape.
- The number of shapes increases with number of dimensions.
- Lack of conformance between similarity and confidence region shapes conservative test
- Conclusion depends on shape choices.

MBSW May 25, 2011

- The confidence level is not the probability of equivalence.
- It is the probability of covering the “true” difference in repeated trials.
- What if you really want to know the probability of equivalence?
- risk based decision making (ICH Q9)

MBSW May 25, 2011

distance estimate: Joint Posterior of

Distance measures

Measure of Equivalence

= Integrated density

= Posterior Probability of Equivalence

Obtained by counting from MCMC

Similarity region

(“customer requirement”)

MBSW May 25, 2011

Probability Model

(Likelihood)

Dissolution Data

(Test and Reference)

Prior Information

(non-informative)

MCMC

Draws from the joint posterior distribution of distance parameters

(10-100 thousand)

Count the fraction of draws within the similarity region

Conclude equivalency if fraction exceeds some limit (e.g. 95%)

MBSW May 25, 2011

6 tablets per lot

MBSW May 25, 2011

% Dissolution vector, Y, for the ith tablet from the kth lot …

MBSW May 25, 2011

MBSW May 25, 2011

MBSW May 25, 2011

and

Since

can be shown (see appendix) to have the distribution

MBSW May 25, 2011

MBSW May 25, 2011

Define a rectangular similarity region, S, as

and require that

to conclude equivalence.

MBSW May 25, 2011

500 of 10,000 draws plotted

MBSW May 25, 2011

MBSW May 25, 2011

% Dissolution vector, y, for the ith tablet from the kth run …

MBSW May 25, 2011

elements of Vtablet

elements of Vrun

Max = 40

MBSW May 25, 2011

Define a rectangular similarity region, S, as

and require that

to conclude equivalence.

MBSW May 25, 2011

1000 of ~2,000 draws plotted

MBSW May 25, 2011

- Data from reference 12
- 3 lots: 1 reference and 2 post-change lots
- A minor change and a major change lot
- 12 tablets per Lot
- Pre-change and Test Lots have different time points

- Comparison requires a parametric dissolution profile model
- Similarity region defined on the model parameter space

MBSW May 25, 2011

Probit:

Logistic:

Weibull:

Exponential:

( 1st order kinetics )

Quadratic:

…and some others (Higuchi, Gompertz, Hixson-Crowell,…)

MBSW May 25, 2011

M measures content

T is time to 63.2% Dissol.

beta measures delay

0.5

2.0

MBSW May 25, 2011

- The following seemed to reduce colinearity and improve convergence.
- Replace T with lna = -b lnT
- Replace b with lnb
- transform time (t) from minutes to hours

MBSW May 25, 2011

% Dissolution, Y, for the ith tablet from the kth lot at the jth time (t) point…

MBSW May 25, 2011

“…At present, some issues are unresolved such as

(i) how many standard deviations (2 or 3) should be

used for a similarity criterion,

(ii) what to do if the ellipse is

only marginally out of the similarity region …”

from Sathe, Tsong, Shah (1996) Pharm Res 13(12) 1799-1803

MBSW May 25, 2011

Prob = 0

2SD Similarity Region

Prob = 0.949

MBSW May 25, 2011

- Pros
- Based on simple counting exercise (MCMC)
- Probability estimate for risk assessment
- Exact conformity between the similarity region and the estimate (integrated posterior)
- Incorporation of prior information (or not) as appropriate
- True equivalence (not significance) test
- Rewards high data information content

- Cons
- Requires (usually) MCMC
- Coverage properties require calibration studies.
- Regulatory acceptance?

MBSW May 25, 2011

- Schuirmann DJ (1981) On hypothesis testing to determine of the mean of a normal distribution is contained in a known interval, Biometrics 37:617
- Berger RL (1982) Multiparameter hypothesis testing and acceptance sampling, Technometrics 24(4) 295-300
- Schuirmann DJ (1987) Comparions of two one-sided procedures and power approach of rassessing the equivalence of average bioavailability, Journal of Pharmokinetics and Biopharmaceutics 15:657-680.
- Shah VP, Yamamoto LA Schirmann D, Elkins J and Skelly JP (1987) Analysis of in vitro dissolution of whole versus half controlled release theophilline tablets, Pharm Res 4: 416-419
- Food and Drug Administration. Guidance for Industry: Immediate Release Solid Oral Dosage Forms. Scale-Up and Postapproval Changes (SUPAC-IR): Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing and In Vivo BE. 1995
- Tsong Y, Sathe P, an dShah VP (1996) Compariong 2 dissolution data sets fro similarity ASA Proceedings of the Biopharmaceutical Section 129-134
- Berger RL and Hsu JC (1996) Bioequivalence trials, intersection-union tests and equivalence confidence sets, Statistical Science 11(4) 283-319
- J.W.Moore and H.H.Flanner, Mathematical Comparison of curves with an emphasis on in vitro dissolution profiles. Pharm. Tech. 20(6), : 64-74, 1996
- Moore JW and Flanner HH (1996) Mathematical comparison of dissolution profiles, Pharmaceutical Technology 24:46-54
- Tsong Y, Hammerstrom T, Sathe P, and Shah VP (1996) Statistical assessment of mean differences between two dissolution data sets, Drug Information Journal 30: 1105-1112
- Polli JE, Rekhi GS, and Shah V (1996) Methods to compare dissolution profiles, Drug Information Journal 30: 1113-1120.
- Sathe PM, Tsong Y, Shah VP (1996) In vitro dissolution profile comparion: statistics and analysis, model dependent approach, Pharmaceutical research 13(12): 1799-1803.
- Polli JE, Rekhi GS, an dShah VP (1996) Methods to compare dissoltuion profiles and a rationale for wide dissoltuion specifications for metroprolol tartrate tablets j pharm Sci 86:690-700
- FDA (1997) Guidance for industry: extended release oral dosage forms: development, evaluation, and application of in vitro/ in vivo correlations
- Food and Drug Administration. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, 1997
- Food and Drug Administration. Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms. 1997
- Chow SD and Ki FYC (1997) Statistical comparison between dissoltuion profiles of drug products, Journal of Biopharmaceutical statistics, 7(30): 241-258
- Tsong Y, Hammerstrom T, an Chen JJ (1997) Multipoint dissoltuion specification and acceptance sampling rule based on profile modeling an dprincipal component analysis, Journal of biopharmaceutical statistics 7(3) 423-439.
- Liu JP, Ma MC, Chow SC (1997) Statistical evaluation of similarity factor f2 as a criterion for assessment of similarity etween dissoltuion profiles Drug Info J 31: 1255-1271
- Ju HL and Liaw S (1997) On the assessment of similarity of drug dissolution profile – a simulation study Drug Info J 31 1273-1289

MBSW May 25, 2011

- Shah VP, Tsong Y, Sathe P, and Liu J-P (1998) In vitro dissolution profile comparisons – statistics and analysis of the similarity factor f2, Pharm. Res. 15: 889-896, 1998
- FDA (2000) Guidance for Industry Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate- Release Solid Oral Dosage Forms Based on Biopharmaceutics Classification System
- FDA (2000) Guidance for industry: bioavailability and Bioequivalence studies for orally administered drug products – general considerations
- Ma M-C, Wang BC, Liu J-P, and Tsong Y (2000) Assessment of similarity between dissolution profiles, Journal of Biopharmaceutical statistics 10(2) 229-249
- Gohel MC and Panchal MK (2000) Comparison of in vitro dissolution profiles using a novel, model independent approach, Pharmaceutical technology, March, 2000, pp 92-102
- Gudrun F (2001) Clinical Data Management - Guidelines for the Registration of Pharmaceuticals -- Notes for Guidance, Points to Consider and Related Documents for Drug Approval with Biostatistical Methodology - Guidelines on Dissolution Profile Comparison, Drug Information Journal, Vol. 35(3), pp 865-874
- FDA (2001) Guidance for industry: statistical approaches to bioequivalence.
- Eaton ML, Muirhead RJ, Steeno GS (2003) Aspects of the dissolution profile testing problem, Biopharmaceutical Report 11(2) 2-7
- Senn S (2001) Statistical issues in bioequivalence, Statistics in Medicine 20: 2785-2799
- Paulo Costa*, Jose´ Manuel Sousa Lobo (2001) Modeling and comparison of dissolution profiles, European Journal of Pharmaceutical Sciences 13, 123–133
- Chow S-C, Shao j, and Wang H (2003) In vitro bioequivalence testing, Statistics in Medicine 22:55-68
- Saranadasa H (2001) Defining similarity of dissolution profiles through Hotelling’s T2 statistic, Pharmaceutical Technology Februrary 2001, pp 46-54
- Tsong Y, Sathe PM, and Shah VP (2003) In vitro dissoltuion profile comparison, pp 456-462, in Encyclopedia of Biopharmaceutical statistics, Marcel Dekker
- Yi Tsong, Meiyu Shen, Vinod P Shah 2004 Three-stage sequential statistical dissolution testing rules. J Biopharm Stat Vol. 14, Issue 3, Pages 757-79
- Saranadasa H and Krishnamoorthy K (2005) A multivariate test for similarity of two dissolution profiles, Journal of Biopharmaceutical Statistics 15, 265-278
- EMEA guidance
- WHO guidance
- J. Siepmann∗, F. Siepmann (2008) Mathematical modeling of drug delivery, International Journal of Pharmaceutics 364 (2008) 328–343
- Selen Arzu; Cruañes Maria T; Müllertz Anette; Dickinson Paul A; Cook Jack A; Polli James E; Kesisoglou Filippos; Crison John; Johnson Kevin C; Muirhead Gordon T; Schofield Timothy; Tsong Yi (Profiled Author: Polli, James E.) 2010Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit. Food and Drug Administration, Silver Spring, Maryland, USA The AAPS journal;12(3):465-72
- Yong Zhang, Meirong Huo, Jianping Zhou, Aifeng Zou, Weize Li, Chengli Yao, and Shaofei Xie (2010) DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution ProfilesThe AAPS Journal, Vol. 12, No. 3, 263-271

MBSW May 25, 2011

MBSW May 25, 2011